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Background/ aim: Since January 2015, the Cystic Fibrosis Newborn Screening (CFNS) program has been implemented in Turkey. We
aimed to evaluate the demographic, clinical, and laboratory data of cases referred from the CFNS program and to determine the most
suitable cut-off value for immunoreactive trypsinogen (IRT)-1 and immunoreactive trypsinogen (IRT-2) that are used in the CFNS
program in Turkey.
Materials and methods: A total of 156 Turkish Caucasian subjects were determined as positive cases during 3 years, from January 2015
to January 2018, and were referred to the pediatric pulmonology clinics of Akdeniz University Hospital, Antalya, Turkey, for the national
CFNS program. The evaluation was made considering the IRT-1 and IRT-2 values, demographic characteristics, sweat test results, CFTR
genotypes, and diagnoses.
Results: Nine patients were diagnosed with cystic fibrosis (CF). Eight were diagnosed with CF-related metabolic syndromes and three
were determined to be CF carriers. The ratio of CF to CF-related metabolic syndrome was determined as 1.1:1. Considering the limits
of the present CFNS program and the IRT method, the positive predictive value (PPV) for the referred cases was determined as 5.8%.
When a cut-off value of 105.6 ng/mL was taken for IRT-1, sensitivity was 100%, specificity was 59%, and PPV was 12.8%. For a cut-off
value of 88.75 ng/mL for IRT-2, sensitivity was determined as 90%, specificity as 65%, and PPV as 15.2%.
Conclusion: This is the first detailed clinical study to evaluate the data from the CFNS program along the Mediterranean coast of
Turkey. As false positive results are extremely high in Turkey, there is an urgent need for revision of the IRT-1 and IRT-2 limits by
evaluating the data of the whole country.
Key words: Immunoreactive trypsinogen, cystic fibrosis newborn screening, IRT cut-off, Turkey

1. Introduction
Newborn screening programs are important in terms
of diagnosing disorders in which intervention before
symptoms can improve outcomes. Within the last 50
years, European countries have started newborn screening
programs for several hereditary diseases within the
framework of public health programs [1,2]. Over the years,
cystic fibrosis newborn screening (CFNS) has become the
main nucleus of these programs. As the first stage in all
CFNS programs, the immunoreactive trypsinogen (IRT)

level is measured in blood samples taken in the first week
of life. The use of IRT in cystic fibrosis (CF) was first
described by Crossley et al. in 1979 [3].
Although an increased IRT level in the first week of
life is a sensitive marker for determination of infants with
CF (OMIM 219700), it is not a specific test. The positive
predictive value (PPV) in samples taken on days 2–5
has been reported to be 3%–10% [4]. There is a need for
a second test to increase the specificity and reduce the
number of referred infants based on the results of the
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sweat test. As a secondary test, the IRT level is usually
remeasured in the 2nd–4th weeks of life, DNA sequencing
analysis is performed to assess the presence of CF-causing
mutations in hotspot regions, and next-generation DNA
sequencing analysis is applied in order to determine
any possible mutation in the whole cystic fibrosis
transmembrane regulator (CFTR; NM_000492) gene
[5]. In secondary stage tests, different factors including
the geographical structure of each country, phenotypicgenetic heterogeneity, and the accessibility of healthcare
resources must be taken into consideration. In countries
with high genetic heterogeneity, as is the case for Turkey,
generally the IRT level assessment is repeated in weeks 2–4
as the secondary test.
When the IRT/IRT method is used as the CFNS
test, its PPV is approximately 50%. It was reported that
perinatal factors such as asphyxial birth, hypoglycemia, or
congenital abnormality caused 25% false-positive results in
the first IRT level. At the same time, other causes including
congenital infection, bowel atresia, renal failure, and some
aneuploidies (trisomies 13 and 18) can be influential on
false-positive results [4]. False-positive results have also
been reported in cases of low birthweight and background
of admittance to the neonatal intensive care unit [6].
It is well known that the reporting of the CFNS
results of a country makes a significant contribution to
the development of screening tests and the control of the
disease. Since the CFNS program just recently started in
2015 in Turkey, there is an urgent need for reporting and
evaluation of the screening program’s results. Therefore,
the main aim of this study was to evaluate the demographic,
clinical, and laboratory data of cases referred to our clinics
based on the obtained data from the national CFNS
program and to determine the most suitable cut-off values
for IRT-1 and IRT-2 values, which are used in the CFNS
program.
2. Materials and methods
In the CFNS program, which has been implemented in
all provinces of Turkey since 2015, heel blood samples are
taken on days 3–7 after birth and are examined using the
fluorometric enzyme immunoassay method, and cases
with IRT levels (IRT-1) of >90 ng/mL are determined. A
second IRT level (IRT-2) measurement is then applied on
days 14–21 after birth. The newborns with IRT-1 of <90 ng/
mL do not give a sample for the second newborn screening
and the result is accepted as a complete process. If the IRT2 level is >70 ng/mL in the cases with high IRT-1, those
infants are accepted as CFNS-positive and are referred to
CF centers for sweat testing. The patients in the current
study determined as CFNS-positive and referred to our
center were separated into 2 groups: Group I comprised
patients diagnosed with CF as a result of further tests and
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Group II comprised those who were not diagnosed with
CF.
The data from 156 Turkish Caucasian patients who
were determined as CF-positive in the national CFNS
program and were referred for sweat testing to the
pediatric pulmonology clinics of Akdeniz University
Hospital between January 2015 to January 2018 were
evaluated. This university hospital is the only CF center
in Antalya Province, located on the south coast of Turkey.
We obtained written approval from the Clinical Research
Ethics Committee of Akdeniz University, Turkey. Data
were retrieved in terms of the medical records of the
time of presentation, parental consanguinity, birthweight,
gestational week at birth, and maternal age.
The chloride level in the sweat test was measured with
the CFΔ Collection System (UCF 2010 Iontophoresis Unit
and UCF 2011 Sweat Analysis Unit), which analyzes the
Cl− concentration of sweat with Coulometric Endpoint
Software [7]. In cases with a chloride (Cl) level of >30
mmol/L in sweat testing, CTFR gene testing was performed,
and after 1 week, follow-up sweat testing was applied.
Molecular genetic analysis of CFTR gene DNA
sequencing was performed using the ABI 3130 Genetic
Analyzer (Life Technologies, USA) to assess the presence
of CF-causing mutations in hotspot exons. Then nextgeneration DNA sequencing analysis (Ion Ampliseq CFTR
Panel) was applied in order to determine any possible
mutations (including deletion and duplication analysis)
in the whole cystic fibrosis transmembrane regulator gene
(CFTR; NM_000492). In next-generation sequencing,
CF panel v2 of the Ion AmpliSeq Panel (Thermo Fisher
Scientific, USA), which screens the whole gene with 102
amplicons (8.49 kb), was used. Targeted next-generation
sequencing analysis was performed (all coding exons,
intron-exon boundaries, and UTR regions). Samples
were multiplexed and sequenced in an Ion S5 System
(Thermo Fisher Scientific, USA). Ion Reporter Software
4.0. (Thermo Fisher Scientific, USA) was used to map the
sequence reads to the GRCh37/hg19 reference genome
and to call the variants. The Ingenuity Variant Analysis
tool (QIAGEN, Germany) was used for annotation and
filtering. Variants listed in the CFMDB, CFTR2, dbSNP,
1000G, and ExAC browsers with >1% minor allele
frequency were also excluded, and the remaining variants
were examined.
Infants with Cl− levels of >60 mmol/L in the sweat test
and/or carrying both mutated CFTR alleles were defined
as CF-positive, those with persistently intermediate
sweat chloride values ranging from 30 to 59 mmol/L and
fewer than 2 CF-causing CFTR mutations or 2 CFTR
mutations with 0 or 1 known to be disease-causing and
sweat chloride concentration <30 mmol/L were defined
as having CF-related metabolic syndrome (CRMS), those
with <30 mmol/L in the sweat test and carrying a single
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mutated allele were defined as CF carriers, and those with
wild genotypes were defined as normal [8,9].
2.1. Statistical analysis
The analysis was conducted using SPSS 23.0 (IBM Corp.,
Armonk, NY, USA). Descriptive statistics were presented
as percentage, mean, standard deviation, median,
minimum, and maximum values. To test the difference of
the numeric variables between groups, the Student t-test
or Mann–Whitney U test was used. To test the difference
of the categorical variables between the groups, the chisquare test was used. Receiver operating characteristic
curve (ROC) analysis was used for determining the best
cut-off value of IRT-1 and IRT-2. A significance level of
95% (or error margin of α = 0.05) was used for determining
the differences in analyses.
3. Results
From 2015 to 2018, 104,255 live births in Antalya Province,
southwest Turkey, were recorded. The newborn screening
test was performed for all of these babies. In the first IRT
screening of this cohort, 1738 newborn babies were found

with IRT-1 levels of >90 ng/mL. In the second test, the IRT
levels of 156 babies were above 70 ng/mL (IRT-2 > 70 ng/
mL) and they were referred to our CF center for further
clinical evaluation. Although the CFNS test result was
negative (IRT-1 level was 270 ng/mL, IRT-2 level was 23
ng/mL), one patient with chronic Pseudomonas aeruginosa
colonization and respiratory problems was diagnosed
with CF. The result of sweat testing for this patient was
28.1 mmol/L and the CFTR genotype was determined as
compound heterozygous, p.R668C/p.G576A.
The 156 Turkish Caucasian patients included in the
study comprised 92 (59%) females and 64 (41%) males.
There was a history of parental consanguinity in 31 (19.9%)
cases. Based on these data, 9 patients were diagnosed with
CF, 8 with CF-related metabolic syndrome, and 3 as CF
carriers. The ratio of CF to CF-related metabolic syndrome
was 1.1:1. The demographic characteristics, the results of
the sweat testing, and the CFTR genotypes of these 20
Turkish Caucasian patients are shown in Table 1.
The mean time of presentation was 41.44 ± 22.86 days
(ranging from 18 to 172 days). The mean of IRT-1 was

Table 1. The demographic characteristics, sweat test results, and CFTR genotypes of the diagnosed patients.
Case

Diagnosis

Sex
(F/M)

Time of
IRT-1
presentation (days) (ng/mL)

IRT-2
(ng/mL)

Cl in sweat
(mmol/L)

CFTR genotype

1

CF*

F

50

171

89

86

c.621+1G>T/[?]

2

CF

M

110

139

156

65

p.ÄF508/p.S549R

3

CF

M

120

110

128

69

p.G1244V/p.G1244 V

4

CF

F

26

303

176

89

p.N1303K/p.N1303K

5

CF

F

34

116

121

47

c.2789+5G>A/ c.2789+5G>A

6

CF

F

63

204

372

79

p.L732X/p.L732X

7

CF

M

69

252

210

108

[?]/[?]

8

CF

F

64

106

93

70

c.2789+5G>A/ c.2789+5G>A

9

CF

M

37

118

131

70

c.406-1G>A/ c.2184insA

10

CF carrier

M

34

98

171

13

p.K68E/ [?]

11

CF carrier

F

40

162

70

9

p.V920L/[?]

12

CF carrier

F

24

169

224

10

p.E217G / [?]

13

CRMS

F

29

142

124

35

[? ]/ [?]

14

CRMS

F

34

160

116

44

p.Y301C/[?]

15

CRMS

M

58

90

90

42

p.L997F/[?]

16

CRMS

M

44

101

70

37

[? ]/ [?]

17

CRMS

F

38

90

70

39

[? ]/ [?]

18

CRMS

M

30

122

70

33

[? ]/ [?]

19

CRMS

M

31

129

86

49

p.F1052V/ [?]

20

CRMS

M

30

125

70

38

p.L997F / [?]

€

£

CF: Cystic fibrosis. €CF carrier: Cystic fibrosis carrier. £CRMS: Cystic fibrosis-related metabolic syndrome. IRT-1: First immunoreactive
trypsinogen level. IRT-2: Second immunoreactive trypsinogen level. F: Female. M: Male. [?] : Unknown.
*
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determined as 115.82 ± 35.9 ng/mL (ranging from 90 to
302.9 ng/mL), the mean of IRT-2 was found as 91.98 ±
35.31 ng/mL (ranging from 70 to 372 ng/mL), the mean
amount of Cl in the sweat was found as 19.06 ± 17.02
mmol/L (ranging from 10 to 108.3 mmol/L), the mean
birthweight was 3162.98 ± 532.42 g (ranging from 1600
to 4500 g), the mean gestational week at birth was 38.71 ±
1.88 weeks (ranging from 29 to 41 weeks), and the mean
maternal age was 28.85 ± 6.29 years (ranging from 18 to
46 years). When the patients were divided between those
diagnosed with CF (Group I) and those not diagnosed
with CF (Group II), no statistically significant difference
was determined between the two groups with respect to
gender, parental consanguinity, and birthweight. In Group
I, a later time of presentation (63.67 ± 32.68 days vs. 40.08
± 21.53 days; P = 0.01), higher IRT-1 level (168.79 ± 70.59
ng/mL vs. 112.58 ± 30.2 ng/mL; P = 0.001), and higher
IRT-2 level (163.93 ± 86.95 ng/mL vs. 87.57 ± 23.89 ng/
mL; P<0.001) were striking, while the gestational week at
birth was lower (36.56 ± 3.32 weeks vs. 38.84 ± 1.69 weeks;
P = 0.007) (Table 2).
As shown in the Figure, the areas under the ROC
curve (AUC) for IRT-1 and IRT-2 in the discrimination
of cystic fibrosis vs. no cystic fibrosis in CFNS were 0.825
(95% confidence interval [CI]: 0.715–0.935) and 0.903
(95% CI: 0.822–0.984) (Figure). When a cut-off value of
105.6 ng/mL was taken for IRT-1, sensitivity was 100%,
specificity was 59%, and PPV was 12.8%. When a cut-off
value of 88.75 ng/mL was taken for IRT-2, sensitivity was
determined as 90%, specificity 65%, and PPV as 15.2%.
Considering the limits of the existing cystic fibrosis
newborn screening program, the PPV of referred cases to
our hospital was determined as 5.8%.
4. Discussion
It is well known that cystic fibrosis is an autosomal
recessive inherited metabolic disorder, which results from

a mutation in the transmembrane conductor regulator
gene and has been included in the Newborn Screening
Program in Turkey since January 2015. To date, the
frequency of cystic fibrosis has been reported as 1/3000 in
Turkey in limited studies; however, it is thought that this
ratio is actually higher due to the consanguinity across the
country [10,11]. This study can be considered valuable as it
is the first regional cohort that has evaluated the data of the
CFNS program from the Mediterranean coast of Turkey.
As a result of the study, it was revealed that the IRT-1 and
IRT-2 values of the CFNS program are higher in CF cases.
We tried to determine the PPV value of the referred cases.
After that, the limits of the existing screening program were
taken into consideration and the PPV of cases referred to
our hospital was determined as 5.8%.
In the European Cystic Fibrosis Association Standards
of Best Practice Guidelines, it is recommended that
national screening programs must aim for a PPV of
at least 30% and sensitivity of 95% [12]. In a study by
Barben et al. [13], the national CFNS programs of sixteen
European countries since 2016 were examined. They
found that ten programs (Northern Ireland, Austria,
France, Russia, Slovakia, Czech Republic, the Netherlands,
Norway, Turkey, and Portugal) used a fixed cut-off for
IRT-1 that ranged from 60 to 90 ng/mL (median: 65 ng/
mL). Six programs (Wales, Scotland, England, Poland,
Ireland, and Switzerland) had a floating cut-off to achieve
a set percentage of samples sent for the next level of
testing (ranging from the 99.0th to 99.5th percentiles).
Four programs (Wales, France, Czech Republic, and
the Netherlands) did not achieve the minimum of 95%
standard for sensitivity, and five programs (Northern
Ireland, Austria, Slovakia, Czech Republic, and Wales)
had a PPV that was lower than the minimum standard of
30%. Ten countries employed a strategy called a ‘safety net’
(also known as ultra-high IRT). In this strategy, patients
whose first IRT value was above the determined high value

Table 2. Comparison of the clinical characteristics of Group I and Group II#.
Group I

Group II

P-value

Sex (%)

44.4%

40.8%

1.00

Consanguinity (% present)

44.4%

18.4%

0.07

Birthweight (g)*

3031.11 ± 617.61

3171.05 ± 528.12

0.62

Time of presentation (days)

63.67 ± 32.68

40.08 ± 21.53

0.01

*

IRT-1 (ng/mL)

168.79 ± 70.54

112.58 ± 30.2

0.001

IRT-2 (ng/mL)*

163.93 ± 86.95

87.57 ± 23.89

<0.001

36.56 ± 3.32

38.84 ± 1.69

0.007

*

Gestational week at birth (weeks)

*

Values are stated as mean ± SD.
Group I: Patients diagnosed with CF as a result of further tests; Group II: those not diagnosed
with CF.
*

#
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Figure. Receiver operating characteristic curve (ROC) for IRT-1 and IRT-2.

were referred for advanced tests even if the second-step
tests were normal. Ultra-high IRT cut-off values were 170
ng/mL in Wales, 100 ng/mL in France, 200 ng/mL in the
Czech Republic, 100 ng/mL in the Netherlands, and 400
ng/mL in Norway. In order to consider these criteria in the
National Cystic Fibrosis Newborn Screening Program in
Turkey, which has extremely high false-positive results, it
is necessary to determine new IRT-1 and IRT-2 limits after
evaluating all the national data. We believe that employing
ultra-high IRT cut-off values can improve the sensitivity
of CFNS tests based on our missed case results. In this
context, the current study can be considered as guidance,
as when a cut-off value of 105.6 ng/mL was considered for
IRT-1, sensitivity was 100%, specificity was 59%, and PPV
was 12.8%, and when a cut-off value of 88.75 ng/mL was
considered for IRT-2, sensitivity was determined as 90%,
specificity as 65%, and PPV as 15.2%.
In the European Cystic Fibrosis Association Standards
of Best Practice Guidelines, it is stated that after CFNS
positivity observation, patients should be seen by a CF
specialist team at mean of 35 days and no later than 58
days [12]. In accordance with these criteria, all the patients
in the current study presented at a mean of 41.44 ± 22.86
days (varying between 18 and 172 days). However, the
mean time of presentation was significantly higher among
the patients diagnosed with CF compared to those not
diagnosed with CF (63.67 ± 32.68 days vs. 40.08 ± 21.53

days; P = 0.01). This discordance can be attributed to
different factors; some patients first presented to another
center because the patients were symptomatic, and
differences exist in sociocultural levels, delay in taking
the second sample, and delay in the transportation of the
sample.
The gestational week at birth in the patients diagnosed
with CF was determined to be significantly lower than
that patients not diagnosed with CF (36.56 ± 3.32 weeks
vs. 38.84 ± 1.69 weeks; P = 0.007). In addition, the mean
birthweight of the patients diagnosed with CF was 140 g
lower compared to those not diagnosed with CF (3031.11
± 617.61 g vs. 3171.05 ± 528.12 g). In 2018, Schlüter et al.
examined the effect of CF on birthweight in Danish and
Welsh populations. The birthweight of CF infants was a
mean of 200 g lower and the birth week was a mean of 1
week earlier compared to infants not diagnosed with CF
[14]. These results demonstrated the effect of CF disease
on the gestational week of birth and birthweight, which
must be taken into consideration.
In a study by Barben et al. [13] examining the national
CFNS programs of thirteen European countries since
2014, the CF to CF-related metabolic syndrome diagnosis
ratio was reported to vary between 32:1 and 1.2:1. Some
countries use DNA analysis of heel blood samples as
a second-line test after IRT-1 to shorten the time of
diagnosis and increase the PPV. This increases the number
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of patients diagnosed as cystic fibrosis carriers and with
CF-related metabolic syndrome. In the current study,
this ratio was determined as 1.1:1, which is lower than in
all the other countries. This outcome may be reasonable
because the diagnostic criteria for CF-related metabolic
syndrome/“CF Screen Positive and Inconclusive
Diagnosis” in Europe have only been clearly determined
since 2015 [15], and we think that the data collected
in the previous period may not have considered these
diagnostic criteria, particularly in countries in which
screening programs were started earlier than in Turkey.
Groves et al. [16] reported that 48% of patients with
CF-related metabolic syndrome diagnosis could be later
diagnosed with CF within 15 years. It must be taken into
account that the number of CF-diagnosed patients in our
study population could increase based on the collection
of whole DNA sequencing analysis data all throughout
the country.
Overall, there are several screening protocols and
algorithms throughout the world. In 2016, Barben et al.
described sixteen different approaches in 16 European
countries [13]. It was concluded that there is no single ideal
screening program method for any country. However, in
light of the data obtained from the CFNS program of any
country, the IRT cut-off values, and the type of CFTR
gene mutations, a screening method can be developed.
Since the identification of the CFTR gene in 1989, more
than 2065 mutations have been identified throughout the
gene to date [17,18]. It is well known that the spectrum
of CFTR mutations varies among different populations,
ethnic backgrounds, and geographical locations [19].
Thus, it is clear that there is no “one-size-fits-all” universal
mutation panel for CF testing in different populations.
Despite the comprehensive screening of the entire CFTR
coding regions, the mutations identified do not account
for 100% of the molecular defects in CF patients. This may
be due to several reasons; there might be mutations deep
in introns that are not analyzed, deletions of exons that
are not PCR-amplified, genetic variations or mutations in
CFTR or other genes adversely affecting CFTR function,

or a CF phenocopy that has the CF clinical phenotype
without mutations in the CFTR gene [20,21].
In our opinion, the reasons why CFNS false positivity
is high in Turkey include the use of fixed cut-off values
for IRT-1 and IRT-2 and the lack of an appropriate cutoff value, and also the lack of DNA sequencing analysis
in the CFNS program. In a previous study [13], Scotland
(sensitivity 100%, PPV 75%) and Ireland (sensitivity
100%, PPV 44%) had the highest sensitivity and positive
predictive values. These two countries use the IRT-DNAIRT method. For IRT-1, a 99.5% floating cut-off is used in
Scotland and a 62 ng/mL fixed cut-off is used in Northern
Ireland. In 2009, Sontag et al. [22] also reported that the
IRT/IRT/DNA model increases the sensitivity of the
screening test and reduces the amount of sweat testing in
Colorado compared with the IRT/IRT model.
In conclusion, screening programs are extremely
important for the early diagnosis of life-changing
diseases, especially for autosomal recessive inherited
fatal genetic diseases. In 2017, the Turkish Statistical
Institute revealed a cross-sectional and national-level
study in 81 provinces that detected a high frequency
(18.5% to 57.8%) of consanguinity both in rural and urban
areas in the Turkish population. There is a high level of
consanguineous marriages all over the country, such as
33.9% on the Mediterranean coast [10], and the rate was
found to be 22%–24% with a resistance to reduction by
Koç et al. in 2017 [11]. Therefore, the efficacy of screening
programs must be carefully evaluated based on the
sociodemographic structure and important risk factors for
each population. Our expert clinical unit is the only CF
center in Antalya Province, on the Mediterranean coast of
Turkey, and has been functioning since 1990. We are aware
that heterogeneous CFTR mutations can cause unusual
electrophysiological or clinical manifestations. Based on
our cohort, there was only one diagnosed case that could
not be determined with the CFNS test. However, although
this is an indication of the high sensitivity of the screening
program, high false-positive values indicate the need for
urgently determining new IRT cut-off values.

References
1.

2.

Loeber JG, Burgard P, Cornel MC, Rigter T, Weinreich SS et
al. Newborn screening programmes in Europe; arguments and
efforts regarding harmonization. Part 1. From blood spot to
screening result. Journal of Inherited Metabolic Disease 2012;
35: 603-611. doi: 10.1007/s10545-012-9483-0
Burgard P, Rupp K, Lindner M, Haege G, Rigter T et al. Newborn
screening programmes in Europe; arguments and efforts
regarding harmonization. Part 2. From screening laboratory
results to treatment, follow-up and quality assurance. Journal
of Inherited Metabolic Disease 2012; 35: 613-625. doi: 10.1007/
s10545-012-9484-z

1660

3.

Crossley JR, Elliott RB, Smith PA. Dried-blood spot screening
for cystic fibrosis in the newborn. Lancet 1979; 1: 472-474. doi:
10.1016/s0140-6736(79)90825-0

4.

Wilcken B. Newborn screening for cystic fibrosis: techniques
and strategies. Journal of Inherited Metabolic Disease 2007; 30:
537-543. doi: 10.1007/s10545-007-0584-0

5.

Southern KW. Determining the optimal newborn screening
protocol for cystic fibrosis. Thorax 2012; 67: 281-282. doi:
10.1136/thoraxjnl-2012-201589

BAŞARAN et al. / Turk J Med Sci
6.

Therrell BL, Hannon WH, Hoffman G, Ojodu J, Farrell PM.
Immunoreactive trypsinogen (IRT) as a biomarker for cystic
fibrosis: challenges in newborn dried blood spot screening.
Molecular Genetics and Metabolism 2012; 106: 1-6. doi:
10.1016/j.ymgme.2012.02.013

7.

Emiralioğlu N, Özçelik U, Yalçın E, Doğru D, Kiper N.
Diagnosis of cystic fibrosis with chloride meter (Sherwood
M926S chloride analyzer®) and sweat test analysis system
(CFΔ collection system ®) compared to Gibson Cooke method.
Turkish Journal of Pediatrics 2016; 56: 27-33. doi: 10.24953/
turkjped.2016.01.004

8.

9.

Paracchini V, Seia M, Raimondi S, Costantino L, Capasso
P et al. Cystic fibrosis newborn screening: distribution
of blood immunoreactive trypsinogen concentrations in
hypertrypsinemic neonates. JIMD Reports 2012; 4: 17-23.
doi: 10.1007/8904_2011_55
Ren CL, Borowitz DS, Gonska T, Howenstine MS, Levy H
et al. Cystic fibrosis transmembrane conductance regulatorrelated metabolic syndrome and cystic fibrosis screen positive,
inconclusive diagnosis. Journal of Pediatrics 2017; 181: 45-51.
doi: 10.1016/j.jpeds.2016.09.066

14.

Schlüter DK, Griffiths R, Adam A, Akbari A, Heaven ML et
al. Impact of cystic fibrosis on birthweight: population based
study of children in Denmark and Wales. Thorax 2019; 74: 44754. doi: 10.1136/thoraxjnl-2018-211706

15.

Munck A, Mayell SJ, Winters V, Shawcross A, Derichs
N et al. Cystic Fibrosis Screen Positive, Inconclusive
Diagnosis (CFSPID): A new designation and management
recommendations for infants with an inconclusive diagnosis
following newborn screening. Journal of Cystic Fibrosis 2015;
14: 706-713. doi: 10.1016/j.jcf.2015.01.001

16.

Groves T, Robinson P, Wiley V, Fitzgerald DA. Long-term
outcomes of children with intermediate sweat chloride values
in infancy. Journal of Pediatrics 2015; 166: 1469-1474. doi:
10.1016/j.jpeds.2015.01.052

17.

Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R
et al. Identification of the cystic fibrosis gene: cloning and
characterization of complementary DNA. Science 1989; 245:
1066-1073. doi: 10.1126/science.2475911

18.

Kerem, B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK
et al. Identification of the cystic fibrosis gene: genetic analysis.
Science 1989; 245: 1073-1080. doi: 10.1126/science.2570460

10.

Alper OM, Erengin H, Manguoğlu AE, Bilgen T, Cetin Z et al.
Consanguineous marriages in the province of Antalya, Turkey.
Annales de Genetique 2004; 47: 129-138. doi: 10.1016/j.
anngen.2003.09.001

19.

Bobadilla JL, Macek M Jr, Fine JP, Farrell PM. Cystic fibrosis:
a worldwide analysis of CFTR mutations--correlation with
incidence data and application to screening. Human Mutation
2002; 19: 575-606. doi: 10.1002/humu.10041

11.

Koç I, Eryurt MA. The causal relationship between
consanguineous marriages and infant mortality in Turkey.
Journal of Biosocial Science 2017; 49: 556. doi: 10.1017/
S002193201600033X

20.

Groman JD, Meyer ME, Wilmott RW, Zeitlin PL, Cutting GR.
Variant cystic fibrosis phenotypes in the absence of CFTR
mutations. New England Journal of Medicine 2002; 347: 401407. doi: 10.1056/NEJMoa011899

12.

Smyth AR, Bell SC, Bojcin S, Bryon M, Duff A et al. European
Cystic Fibrosis Society Standards of Care: Best practice
guidelines. Journal of Cystic Fibrosis 2014; 13: 23-42. doi:
10.1016/j.jcf.2014.03.010

21.

Başaran AE, Karataş-Torun N, Maslak İC, Bingöl A, Alper ÖM.
Normal sweat chloride test does not rule out cystic fibrosis.
Turkish Journal of Pediatrics 2017; 59: 68-70. doi: 10.24953/
turkjped.2017.01.011

13.

Barben J, Castellani C, Dankert-Roelse J, Gartner S, Kashirskaya
N et al. The expansion and performance of national newborn
screening programs for cystic fibrosis in Europe. Journal of
Cystic Fibrosis 2017; 16: 207-213. doi: 10.1016/j.jcf.2016.12.012

22.

Sontag MK, Wright D, Beebe J, Accurso FJ, Sagel SD. A new
cystic fibrosis newborn screening algorithm: IRT/IRT1 upward
arrow/DNA. Journal of Pediatrics 2009; 155: 618-622. doi:
10.1016/j.jpeds.2009.03.057

1661

